Press Releases

Date Title and Summary
Toggle Summary Abbott and Isis Announce Hart-Scott-Rodino Clearance of Abbott's Acquisition of Ibis Biosciences, a Subsidiary of Isis
Toggle Summary Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
Toggle Summary Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
Toggle Summary Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences
Toggle Summary ADA Conference Presentations Highlight Isis' Metabolic Disease Program Research Activities
Toggle Summary Advances in Ionis' Novel Antisense Technology to be Presented at 2018 Society for Neuroscience Meeting
12 presentations highlighting latest data from Ionis' Neurodegenerative Program including first-in-class therapies for untreatable diseases such as Alzheimer's, ALS, Alexander, and spinocerebellar ataxia type 3 CARLSBAD, Calif. , Oct. 31, 2018 /PRNewswire/ --  Ionis Pharmaceuticals, Inc.
Toggle Summary Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS
FDA Prescription Drug User Fee Act goal date set for August 30, 2018 CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious
Toggle Summary Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada
First and only treatment of its kind for Canadians with Hereditary Transthyretin-mediated Amyloidosis (hATTR amyloidosis) with Polyneuropathy – a rare and inherited disease OTTAWA and BOSTON and CARLSBAD, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics Inc.
Toggle Summary Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen) in the European Union
CAMBRIDGE, Mass. and CARLSBAD, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), announced today that TEGSEDI TM (inotersen) has received marketing authorization approval
Toggle Summary Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada
Health Canada grants priority review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.